Pacific Biosciences of California shares are trading higher after Goldman Sachs initiated coverage on the stock with a Buy rating and a $17 price target.
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs has initiated coverage on Pacific Biosciences of California with a Buy rating and a $17 price target. This has led to an increase in the company's share price.
June 30, 2023 | 1:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pacific Biosciences' stock is trading higher after Goldman Sachs initiated coverage with a Buy rating and a $17 price target.
The Buy rating and price target set by Goldman Sachs, a reputable financial institution, has increased investor confidence in Pacific Biosciences, leading to a rise in its stock price. This is likely to have a positive short-term impact on the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100